Quantcast

Medtronic Data Expands on Key Aortic Solutions for Challenging Anatomies

By GlobeNewswire,  April 17, 2019, 06:00:00 AM EDT


New EndoSuture Aneurysm Repair (ESAR) and Valiant Navion(TM) Data Presented at Charing Cross Demonstrate Safety and Efficacy in Patients with Complex Anatomies

DUBLIN and LONDON - April 17, 2019 -Medtronic plc (NYSE:MDT) today released new data on endovascular repair of abdominal aortic aneurysm (AAA) patients with the Endurant(TM) II/IIs stent graft system in combination with Heli-FX(TM) EndoAnchor(TM) implants and for the Valiant Navion(TM) thoracic stent graft system for thoracic endovascular repair (TEVAR). The data presented at the Charing Cross Symposium in London expands on the commitment to treat increasingly challenging aortic anatomies.

Two-Year Endosuture Aneurysm Repair (ESAR) Data

Medtronic shared preliminary two-year data supporting the safety, durability, and effectiveness of Endurant to treat AAA patients with short aortic necks when used in combination with the Heli-FX(TM) EndoAnchor(TM) system. Results from the ANCHOR Registry (a global multi-center, multi-arm, prospective, post-market registry evaluating the real-world applicability of the Heli-FX EndoAnchor system) two-year sub-analysis were presented for the first time by Frank R. Arko III, M.D., chief, Vascular and Endovascular surgery, professor, Cardiovascular Surgery and co-director, Aortic Institute, Carolinas Medical Center, Sanger Heart and Vascular Institute Charlotte, North Carolina.

Up to 30 to 40 percent of patients with AAA disease are considered unsuitable candidates for conventional endovascular aneurysm repair (EVAR).1 According to estimates from physicians across Europe and the United States, more than one-third of these patients have AAA proximal neck anatomies <= 10mm.2 Until recently, limited treatment options were available for these AAA patients with short infra-renal necks (<10mm) specifically.

One-year outcomes from 70 patients enrolled with short infra-renal necks (<10mm) have been previously presented and published in the Journal of Vascular Surgery. The results of the first 38 patients to reach two-year imaging follow-up were presented at Charing Cross 2019. Through two years, freedom from aneurysm-related mortality was 94.3 percent and freedom from secondary endovascular procedure was 95.5 percent, with only one patient requiring a proximal neck-related reintervention. Per core lab assessment, at two years there were no new or persistent type Ia endoleaks. Additionally, 64.7 percent of Endurant + Heli-FX short neck patients experienced AAA sac regression > 5mm, and none experienced AAA sac enlargement through two-years. Finally, no AAA ruptures or stent graft main body migrations were reported through two years.

"By using an EndoSuture aneurysm repair (ESAR) approach with the Endurant stent graft and the Heli-FX EndoAnchor system, physicians are able to safely and effectively treat a wider range of patients with short aortic neck anatomies, independent of renal stenting," said Dr. Arko. "At two years, the preliminary data also demonstrate that 100 percent of sacs are either shrinking or stable-an indicator of EVAR durability."

Valiant Navion 30-day Full Patient Cohort Data

New data from the full patient cohort of the pivotal Valiant Navion study were also presented by Professor Fabio Verzini, M.D., Ph.D., associate professor of Vascular Surgery, University of Turin, Italy and European principal investigator for the Valiant Navion IDE study. The 30-day analysis included the full 100 subjects enrolled in the international, multicenter, prospective investigational device exemption (IDE) study analyzing the safety and efficacy of Valiant Navion in subjects with thoracic aortic aneurysm (TAA) and penetrating atherosclerotic ulcer (PAU). The results demonstrated safety and efficacy in both FreeFlo and CoveredSeal configurations, with no instances of access or deployment failures at implant in the full study cohort. Through 30 days, data showed low rates of peri-operative mortality at 2.0 percent and secondary procedures at 2.0 percent. The rate of Type Ia endoleaks was 1.1 percent at one-month imaging follow-up.

The Valiant Navion system is a lower-profile evolution of the market-leading Valiant(TM) Captivia(TM) thoracic stent graft system-a device that has been used to treat more than 100,000 patients globally. Valiant Navion is built on the design philosophy of the Valiant Captivia system for improved flexibility and conformability, as well as increased patient applicability to address multiple challenging pathologies of the thoracic aorta. The system also features the CoveredSeal (proximal covered) and FreeFlo (proximal bare metal) stent configurations - both with tip-capture accuracy. The low profile Valiant Navion was specifically designed to effectively treat underlying pathologies while minimizing the potential impact to the aortic wall, particularly in fragile aortas.

"We are achieving success by innovating technology to treat more challenging anatomies and building confidence in our aortic pipeline through transparency in clinical data reporting," said John Farquhar, vice president and general manager of the Aortic business, which is part of the Aortic, Peripheral, and Venous division at Medtronic. "Our dedication to addressing critical patient needs with solutions that are safe and improve outcomes is evident."

In collaboration with leading clinicians, researchers, and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services of the highest quality that deliver clinical and economic value to healthcare consumers and providers around the world.

About Medtronic

Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 86,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

-end-

1 Skelly, Christopher L., and Ross Milner. Difficult Decisions in Vascular Surgery: an Evidence-Based Approach. Springer, 2017.

2 Medtronic data on file.

  

 

Contacts:

Julia Fuller

Public Relations

+1-858-692-2001



Ryan Weispfenning

Investor Relations

+1-763-505-4626







This announcement is distributed by West Corporation on behalf of West Corporation clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Medtronic plc via Globenewswire



This article appears in: News Headlines

Referenced Stocks: MDT










Today's Market Activity

NASDAQ 7993.76
-4.30  ▼  0.05%
DJIA 26508.07
-51.47  ▼  0.19%
S&P 500 2903.79
-1.24  ▼  0.04%
Data as of Apr 22, 2019 | 10:33AM